已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Vemurafenib for BRAF V600–Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study

威罗菲尼 医学 V600E型 朗格汉斯细胞组织细胞增多症 内科学 无进展生存期 黑色素瘤 肿瘤科 不利影响 正电子发射断层摄影术 皮肤病科 癌症研究 放射科 化疗 疾病 突变 转移性黑色素瘤 化学 基因 生物化学
作者
Eli L. Diamond,Vivek Subbiah,Albert Craig Lockhart,Jean‐Yves Blay,Igor J. Puzanov,Ian Chau,Noopur S Raje,Jürgen Wolf,Joseph Patrick Erinjeri,Jean M. Torrisi,Mario E. Lacouture,Elena Élez,Fernando Martínez‐Valle,Benjamin Heath Durham,Maria E. Arcila,Gary A. Ulaner,Omar Ibrahim Abdel-Wahab,Bethany Pitcher,Martina Makrutzki,Todd Riehl
出处
期刊:JAMA Oncology [American Medical Association]
卷期号:4 (3): 384-384 被引量:464
标识
DOI:10.1001/jamaoncol.2017.5029
摘要

IMPORTANCE: The histiocytic neoplasms Erdheim-Chester disease (ECD) and Langerhans cell histiocytosis (LCH) are highly enriched for BRAF V600 mutations and have been previously shown to be responsive to treatment with vemurafenib, an inhibitor of the BRAF V600 kinase. However, the long-term efficacy and safety of prolonged vemurafenib use in these patients are not defined. Here we analyze the final efficacy and safety data for vemurafenib in patients with ECD and LCH enrolled in the VE-BASKET study. OBJECTIVE: To determine the efficacy and safety of vemurafenib in adults with ECD or LCH enrolled in the VE-BASKET study. DESIGN, SETTING, AND PARTICIPANTS: The VE-BASKET study was an open-label, nonrandomized, multicohort study for patients with nonmelanoma cancers harboring the BRAF V600 mutation. Patients with BRAF V600-mutant ECD or LCH were enrolled in an "other solid tumor" cohort of the VE-BASKET study, and they were enrolled in the present study. INTERVENTIONS: Patients received vemurafenib, 960 mg, twice daily continuously until disease progression, study withdrawal, or occurrence of intolerable adverse effects. MAIN OUTCOMES AND MEASURES: The primary end point was confirmed objective response rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST, version 1.1). Secondary end points included progression-free survival (PFS), overall survival (OS), metabolic response by modified positron-emission tomography (PET) Response Criteria in Solid Tumors (PERCIST) using 18F-fluorodeoxyglucose (FDG)-PET/computed tomography (CT), and safety. RESULTS: A total of 26 patients from the VE-BASKET trial (22 with ECD, 4 with LCH) were included in the present study (14 women and 12 men; median age, 61 years; age range, 51-74 years). The confirmed ORR was 61.5% (95% CI, 40.6%-79.8%) in the overall cohort and 54.5% (95% CI, 32.2%-75.6%) in patients with ECD. All evaluable patients achieved stable disease or better. The median PFS and OS had not been reached in the overall cohort at study closure despite a median follow-up of 28.8 months; 2-year PFS was 86% (95% CI, 72%-100%), and 2-year OS was 96% (95% CI, 87%-100%). All 15 patients evaluated by FDG-PET/CT achieved a metabolic response, including 12 patients (80%) with a complete metabolic response. The most common adverse events (AEs) in the overall cohort included arthralgia, maculopapular rash, fatigue, alopecia, prolonged QT interval, skin papilloma, and hyperkeratosis. Hypertension and dermatologic AEs occurred at higher rates than those reported in metastatic melanoma. CONCLUSIONS AND RELEVANCE: In this study, vemurafenib had prolonged efficacy in patients with BRAF V600-mutant ECD and LCH and warrants consideration as a new standard of care for these patients.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
骁龙完成签到 ,获得积分10
1秒前
小橙完成签到 ,获得积分10
1秒前
GU完成签到 ,获得积分10
1秒前
3秒前
Stella完成签到,获得积分10
4秒前
5秒前
栓财完成签到 ,获得积分10
5秒前
iceicefdtd发布了新的文献求助10
7秒前
余鱼鱼完成签到,获得积分10
7秒前
7秒前
LERRY完成签到,获得积分10
7秒前
卡皮巴拉完成签到 ,获得积分10
8秒前
莫力布林完成签到 ,获得积分10
8秒前
Ava的应助被KianKarimi147采纳,获得40
9秒前
NexusExplorer的应助被林夏采纳,获得10
9秒前
曾经凌萱发布了新的文献求助10
10秒前
10秒前
123嗯呐完成签到,获得积分10
10秒前
sun完成签到,获得积分10
10秒前
的速度发布了新的文献求助10
12秒前
15秒前
糊涂的箴完成签到,获得积分10
16秒前
16秒前
科研通AI6.4的应助被曾经凌萱采纳,获得10
16秒前
烟花的应助被曾经凌萱采纳,获得10
16秒前
Jasper的应助被珊啊是珊珊啊采纳,获得10
18秒前
耶耶完成签到 ,获得积分10
18秒前
piupiu完成签到,获得积分10
19秒前
20秒前
20秒前
jie完成签到 ,获得积分10
20秒前
21秒前
21秒前
21秒前
21秒前
22秒前
22秒前
22秒前
torfun发布了新的文献求助10
22秒前
22秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8189908
求助须知:如何正确求助?哪些是违规求助? 9577068
关于积分的说明 21851352
捐赠科研通 7787862
什么是DOI,文献DOI怎么找? 3435817
关于科研通互助平台的介绍 2559861
邀请新用户注册赠送积分活动 2482718